HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 1,657-1,668 of 4,505
Drug study icon
TerminatedNCT00917293

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia

Official study title

A Randomized, Double-Blind, Placebo-Controlled, Comparative Study to Evaluate the Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia in Patients With Schizophrenia and Schizoaffective Disorders

This study ended early.

Multiple locations, including Victoria
SchizophreniaMedication studyAges 18–65
Countries
Canada, India
Sponsor
Medicure
Drug study icon
TerminatedNCT00686699

Preladenant for schizophrenia

Official study title

A Phase 2a, Multiple Dose, Placebo Controlled, Randomized, Two Way Crossover Study to Assess the Efficacy of SCH 420814 in Reducing Anti Psychotic-Induced Extra Pyramidal Symptoms Among Subjects With Schizophrenia and Schizoaffective Disorders

This study ended early.

Location not clearly listed
SchizophreniaMedication studyAges 18–65
Countries
Sponsor
Merck Sharp & Dohme LLC
Device study icon
WithdrawnNCT04513132

Targeted Intervention Study of DTMS on Impaired Insight in Early Psychosis

Official study title

A Study on Targeted Intervention for Insight in Patients with First Episode and Clinical High Risk of Schizophrenia Based on Theta Oscillation in Anterior Cingulate Cortex

This study was withdrawn before enrollment.

In Shanghai
SchizophreniaDevice studyAges 15–35
Countries
China
Sponsor
Shanghai Mental Health Center
Drug study icon
CompletedNCT01082250

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Official study title

AN OPEN-LABEL, RANDOMIZED, THREE-PERIOD, TWO-SEQUENCE CROSSOVER, REPEATED-DOSE, REPLICATE DESIGN STUDY TO DETERMINE THE BIOEQUIVALENCE OF TWO DIFFERENT LURASIDONE FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA, SCHIZOAFFECTIVE, OR SCHIZOPHRENIFORM DISORDER

This study has finished and is no longer accepting participants.

In Glendale
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Sumitomo Pharma America, Inc.
Drug study icon
TerminatedNCT03230097

This Study Tests Whether BI 409306 Prevents people with a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Official study title

A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.

This study ended early.

Multiple locations, including Culver City
SchizophreniaMedication studyAges 16–30
Countries
United States, Canada, United Kingdom, + 1 other
Sponsor
Boehringer Ingelheim
Drug study icon
CompletedNCT00053703

Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)

Official study title

Treatment of Schizophrenia and Related Disorders in Children and Adolescents

This study has finished and is no longer accepting participants.

Multiple locations, including Medford
SchizophreniaMedication studyAges 8–19
Countries
United States
Sponsor
University of North Carolina, Chapel Hill

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.